| 1 |
Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease[J]. Lancet, 2022, 399(10342): 2227-2242.
|
| 2 |
Lu W, Aarsand R, Schotte K, et al. Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary[J]. Respir Res, 2024, 25(1): 338.
|
| 3 |
Boers E, Allen A, Barrett M, et al. Forecasting the Global Economic and Health Burden of COPD From 2025 Through 2050[J]. Chest, 2025, 168(4): 880-889.
|
| 4 |
Macintyre NR. Acute hypercapnic respiratory failure in COPD[J]. Respir Care, 2023, 68(7): 973-982.
|
| 5 |
Maia IS, Kawano-Dourado L, Tramujas L, et al. High-flow nasal oxygen vs noninvasive ventilation in patients with acute respiratory failure: The RENOVATE randomized clinical trial[J]. JAMA, 2025, 333(10): 875-890.
|
| 6 |
葛敏，朱祥，晁东鹏，等. 布地格福吸入气雾剂联合可加温湿化的经鼻氧疗与无创正压通气治疗慢性阻塞性肺疾病并发Ⅱ型呼吸衰竭患者的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(5): 762-767.
|
| 7 |
Xu Z, Zhu L, Zhan J, et al. The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type Ⅱ respiratory failure: a meta-analysis and systematic review[J]. Eur J Med Res, 2021, 26(1): 122.
|
| 8 |
Ramírez-venegas A, Montiel-lopez F, Robles-hernández RE, et al. Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass[J]. ERJ Open Res, 2024, 10(6): 00154-02024.
|
| 9 |
Koarai A, Yamada M, Ichikawa T, et al. Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: A systematic review and meta-analysis[J]. Respir Investig, 2022, 60(1): 90-98.
|
| 10 |
Sun J, Xu X, Wang F. Comparison of the efficacy of noninvasive positive pressure ventilation combined with and without budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in the treatment of acute exacerbations of Chronic Obstructive Pulmonary Disease[J]. Pak J Med Sci, 2025, 41(4): 1157-1163.
|
| 11 |
Heo YA. Budesonide/glycopyrronium/formoterol: a review in COPD[J]. Drugs, 2021, 81(12): 1411-1422.
|
| 12 |
Ismaila AS, Haeussler K, Czira A, et al. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: A Network Meta-analysis[J]. Adv Ther, 2022, 39(9): 3957-3978.
|
| 13 |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志，2021, 44(3): 170-205.
|
| 14 |
Rochwerg B, Brochard L, Elliottm W, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure[J]. Eur Respir J, 2017, 50(2): 1602426.
|
| 15 |
Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test[J]. Eur Respir J, 2009, 34(3): 648-654.
|
| 16 |
Nonato NL, Díaz O, Nascimento OA, et al. Behavior of quality of life (SGRQ) in COPD patients according to BODE scores[J]. Arch Bronconeumol, 2015, 51(7): 315-321.
|
| 17 |
Huang CT, Ruan SY, Tsai YJ, et al. Lung fluid content during 6MWT in patients with COPD with and without comorbid heart failure[J]. BMJ Open Respir Res, 2024, 11(1): e002000.
|
| 18 |
Ringle ES, Stark MM, Freeseman-freeman L, et al. Where is acute physiology and chronic health evaluation V？[J]. Crit Care Med, 2021, 49(11): e1176-e1177.
|
| 19 |
Buhl R, Dreher M, Mattiucci-guehlke M, et al. EVELUT®：A real-world, observational study assessing dyspnoea and symptom burden in COPD patients switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS[J]. Adv Ther, 2023, 40(7): 3263-3278.
|
| 20 |
Feldman WB, Avorn J, Kesselheim AS, et al. Chronic obstructive pulmonary disease exacerbations and pneumonia hospitalizations among new users of combination maintenance inhalers[J]. JAMA Intern Med, 2023, 183(7): 685-695.
|
| 21 |
Rogliani P, Ora J, Cavalli F, et al. Comparing the efficacy and safety profile of triple fixed-dose combinations in COPD: A Meta-analysis and IBiS score[J]. J Clin Med, 2022, 11(15): 4491.
|
| 22 |
Bourdin A, Molinari N, Ferguson GT, et al. Efficacy and safety of budesonide/glycopyrronium/formoterol fumarate versus other triple combinations in COPD: A systematic literature review and Network Meta-analysis[J]. Adv Ther, 2021, 38(6): 3089-3112.
|
| 23 |
Farmer M, Callahan C D, Hughes A, et al. Applying noninvasive ventilation in treatment of acute exacerbation of COPD using evidence-based interprofessional clinical practice[J]. Chest, 2024, 165(6): 1469-1480.
|
| 24 |
Sposato B, Ricci A, Lacerenza LG, et al. Triple therapy in COPD in real life: Is it better to use single or multiple inhalers？[J]. J Clin Med, 2024, 13(20): 6191.
|
| 25 |
Mannino D, Dirocco K, Germain G, et al. Fluticasone furoate/umeclidinium/vilanterol initiation following a COPD exacerbation: Benefits of prompt initiation on COPD outcomes[J]. Adv Ther, 2024, 41(12): 4557-4580.
|
| 26 |
Muro S, Kawayama T, Sugiura H, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history[J]. Respir Res, 2024, 25(1): 297.
|
| 27 |
Zhang Y, Tan X, Hu S, et al. Relationship between systemic immune-inflammation index and risk of respiratory failure and death in COPD: A retrospective cohort study based on the MIMIC-Ⅳ database[J]. Int J Chron Obstruct Pulmon Dis, 2024, 19: 459-473.
|
| 28 |
Xu C, Yang F, Wang Q, et al. Comparison of high flow nasal therapy with non-invasive ventilation and conventional oxygen therapy for acute hypercapnic respiratory failure: A Meta-analysis of randomized controlled trials[J]. Int J Chron Obstruct Pulmon Dis, 2023, 18: 955-973.
|
| 29 |
Pitre T, Abbasi S, Kachkovski GV, et al. Home respiratory strategies in patients with COPD with chronic hypercapnic respiratory failure[J]. Respir Care, 2024, 69(11): 1457-1467.
|
| 30 |
任婷婷，焦伟，丁成红，等. 布地格福吸入气雾剂与氟替美维吸入粉雾剂治疗中重度慢性阻塞性肺疾病稳定期有效性与安全性比较[J]. 中国药业，2024, 33(11): 84-87.
|